Please login to the form below

Not currently logged in
Email:
Password:

Gilead Sciences in US investigation

Gilead Sciences is having its manufacturing and distribution practices investigated by the US Attorney's Office

Gilead Sciences has received a subpoena from the US Attorney's Office for the Northern District of California requesting documents related to the manufacture, and related quality and distribution practices of its HIV and hepatitis B drugs.

The subpoena involves the drugs Atripla (efavirenz tenofovir emtricitabine), Emtriva (emtricitabine), Hepsera (adefovir dipivoxil), Letairis (ambrisentan), Truvada (tenofovir emtricitabine), Viread (tenofovir) and its investigational fixed-dose combination of Truvada and Edurant (rilpivirine).

In a statement the company said it is cooperating with the civil and criminal investigation.

The case could take years to resolve and is likely to result in a substantial fine.

14th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics